The field of RNA therapeutics has expanded incredibly in the past 30 years, and mRNA-based COVID-19 vaccines were just the start.
The Omicron strain is driving a rapid increase in China, and is quicker to transmit than other variants.
The rapidly-mutating SARS-CoV-2 virus is testing the resilience of the world’s responses, with some variants evolving to become more infectious, and threatening a third wave.
The case is growing stronger for COVID-19 vaccine mixing-and-matching, with recent data showing high efficacy and protection against SARS-CoV-2 virus strains.
Dr Harry Al-Wassiti, Research Fellow at the Monash Institute of Pharmaceutical Sciences (MIPS), answers the questions about the jab that's on everyone's mind.
A behind-the-scenes look at the two vaccine candidates being developed by Monash University and the Doherty Institute.
How likely is it that we'll have a relatively quick fix for COVID-19, and what are the hurdles?
Eureka Prize-winning data mining techniques are being utilised in areas as diverse as drug use research and medicine.
Dummy text
